|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US6559279B1
(en)
*
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
NO20004795D0
(en)
*
|
2000-09-26 |
2000-09-26 |
Nycomed Imaging As |
Peptide-based compounds
|
|
US20050054836A1
(en)
*
|
2000-11-09 |
2005-03-10 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
|
US6878805B2
(en)
*
|
2002-08-16 |
2005-04-12 |
Isis Pharmaceuticals, Inc. |
Peptide-conjugated oligomeric compounds
|
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
|
WO2004044141A2
(en)
*
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
|
US6913890B2
(en)
|
2002-12-18 |
2005-07-05 |
Palo Alto Research Center Incorporated |
Process for preparing albumin protein conjugated oligonucleotide probes
|
|
US20080015349A1
(en)
*
|
2003-01-24 |
2008-01-17 |
Third Wave Technologies, Inc. |
Oligonucleotide production
|
|
DE602004028930D1
(en)
|
2003-04-29 |
2010-10-14 |
Avi Biopharma Inc |
COMPOSITIONS FOR IMPROVING ANTISENSE EFFECTIVENESS AND TRANSPORT OF NUCLEIC ACID ANALOGUE IN CELLS
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
CA2568735A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
EP3808845A1
(en)
*
|
2004-06-28 |
2021-04-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
EP1695717A1
(en)
*
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007137301A2
(en)
*
|
2006-05-23 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of chrebp expression
|
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
US7919581B2
(en)
*
|
2007-07-31 |
2011-04-05 |
Burnham Institute For Medical Research |
Bi-dentate compounds as kinase inhibitors
|
|
US20100280098A1
(en)
*
|
2007-10-05 |
2010-11-04 |
Juliano Rudolph L |
Receptor targeted oligonucleotides
|
|
JP5788312B2
(en)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomal degradable components
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
CA2743981C
(en)
|
2008-09-22 |
2019-01-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
|
US8962580B2
(en)
|
2008-09-23 |
2015-02-24 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
|
BR122020021379B1
(en)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
morpholino phosphorodiamidate oligomer, composition comprising the same and use of said oligomer to treat muscular dystrophy
|
|
CA2743136C
(en)
|
2008-11-10 |
2019-02-26 |
Muthiah Manoharan |
Novel lipids and compositions for the delivery of therapeutics
|
|
ES2616051T3
(en)
|
2008-12-02 |
2017-06-09 |
Wave Life Sciences Japan, Inc. |
Method for the synthesis of modified nucleic acids in the phosphorus atom
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US20100190691A1
(en)
*
|
2009-01-27 |
2010-07-29 |
Trojan Technologies, Ltd |
Delivery of nucleic acids using cell-penetrating peptides
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
EP3424939A1
(en)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
|
EP2440183B1
(en)
|
2009-06-10 |
2018-07-18 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
KR101885383B1
(en)
|
2009-07-06 |
2018-08-03 |
웨이브 라이프 사이언시스 리미티드 |
Novel nucleic acid prodrugs and methods of use thereof
|
|
DK2499249T3
(en)
|
2009-11-12 |
2018-12-03 |
Univ Western Australia |
ANTISENCE MOLECULES AND PROCEDURES FOR TREATING PATHOLOGIES
|
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CN103119054B
(en)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
VISTA regulatory T cell mediator protein, VISTA binding agent and use thereof
|
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
WO2011163121A1
(en)
|
2010-06-21 |
2011-12-29 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
|
WO2011163401A2
(en)
|
2010-06-22 |
2011-12-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
|
SG10201508118WA
(en)
|
2010-09-30 |
2015-11-27 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
|
DK2643018T3
(en)
|
2010-11-23 |
2021-01-18 |
Vitaeris Inc |
ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
|
|
DK3202760T3
(en)
|
2011-01-11 |
2019-11-25 |
Alnylam Pharmaceuticals Inc |
PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
ES2765874T3
(en)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
|
CN107365339A
(en)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
Methods of Synthesizing Functionalized Nucleic Acids
|
|
EP3456317B1
(en)
|
2011-09-27 |
2025-09-24 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
BR112014032276A2
(en)
|
2012-06-22 |
2017-11-28 |
King S College London |
vista-ig constructs and the use of vista-ig for the treatment of autoimmune, allergic and inflammatory disorders
|
|
RU2693381C2
(en)
|
2012-07-13 |
2019-07-02 |
Уэйв Лайф Сайенсес Лтд. |
Asymmetric auxiliary group
|
|
WO2014012081A2
(en)
|
2012-07-13 |
2014-01-16 |
Ontorii, Inc. |
Chiral control
|
|
BR112015000723A2
(en)
|
2012-07-13 |
2017-06-27 |
Shin Nippon Biomedical Laboratories Ltd |
chiral nucleic acid adjuvant
|
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
MY173826A
(en)
|
2012-11-15 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
EP3336104A1
(en)
|
2012-12-28 |
2018-06-20 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
|
AU2014236140B2
(en)
|
2013-03-14 |
2019-10-03 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
WO2014144978A2
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
|
EP3087098B1
(en)
|
2013-12-24 |
2020-04-08 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
WO2015108048A1
(en)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
PT3094728T
(en)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Chiral design
|
|
CN106661580B
(en)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
Antisense oligonucleotides for treating pompe disease
|
|
JP6997619B2
(en)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity
|
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
|
JP2018504380A
(en)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
REVERSIR ™ compounds
|
|
HK1252759A1
(en)
|
2015-05-19 |
2019-05-31 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2016196897A1
(en)
|
2015-06-04 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
EP3313882B1
(en)
|
2015-06-24 |
2020-03-11 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
JP2018520683A
(en)
|
2015-07-17 |
2018-08-02 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Multi-target single-body conjugates
|
|
US10993995B2
(en)
|
2015-12-07 |
2021-05-04 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
|
EP3413910A1
(en)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5) antibodies
|
|
AU2017250294B2
(en)
|
2016-04-15 |
2022-07-21 |
Immunext Inc. |
Anti-human VISTA antibodies and use thereof
|
|
EA039716B1
(en)
*
|
2016-05-17 |
2022-03-03 |
Сарепта Терапьютикс, Инк. |
Peptide-oligonucleotide conjugates
|
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
|
WO2018035380A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
HUE059843T2
(en)
|
2016-12-19 |
2023-01-28 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
EP3645546A4
(en)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
CHIRAL PHOSPHORAMIDITE AIDS AND METHOD FOR THEIR USE
|
|
KR20210018267A
(en)
|
2018-05-07 |
2021-02-17 |
알닐람 파마슈티칼스 인코포레이티드 |
Extrahepatic delivery
|
|
WO2020069055A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
US20220211743A1
(en)
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
CN119709746A
(en)
|
2019-11-06 |
2025-03-28 |
阿尔尼拉姆医药品有限公司 |
Extrahepatic delivery
|
|
KR102397922B1
(en)
*
|
2020-02-19 |
2022-05-13 |
서울대학교 산학협력단 |
Novel tumor-associated antigen protein OLFM4 and the use thereof
|
|
WO2021168575A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Quadrumix Biotechnology Inc. |
Polypeptides directed against viral infection and uses thereof
|
|
CN115484932B
(en)
|
2020-03-04 |
2024-12-10 |
维乎医疗有限公司 |
Compositions and methods for targeted RNA delivery
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
CN116368226A
(en)
|
2020-09-04 |
2023-06-30 |
维乎医疗有限公司 |
Compositions and methods for capping RNA
|
|
KR20230136130A
(en)
|
2020-12-31 |
2023-09-26 |
알닐람 파마슈티칼스 인코포레이티드 |
Cyclic-disulfide modified phosphate-based oligonucleotide prodrug
|
|
US20240336914A1
(en)
|
2020-12-31 |
2024-10-10 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
|
MX2024004437A
(en)
|
2021-10-15 |
2024-07-01 |
Alnylam Pharmaceuticals Inc |
Extra-hepatic delivery irna compositions and methods of use thereof.
|
|
CN114644684B
(en)
*
|
2022-02-14 |
2023-06-27 |
浙江大学杭州国际科创中心 |
Cell membrane penetrating peptide and application thereof
|
|
US20250304957A1
(en)
|
2022-05-13 |
2025-10-02 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
EP4547683A2
(en)
|
2022-06-30 |
2025-05-07 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
|
TW202449152A
(en)
|
2023-02-09 |
2024-12-16 |
美商艾拉倫製藥股份有限公司 |
Reversir molecules and methods of use thereof
|
|
AU2024254919A1
(en)
|
2023-04-12 |
2025-10-30 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery of double-stranded rna agents
|
|
WO2024238385A2
(en)
|
2023-05-12 |
2024-11-21 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025194075A1
(en)
*
|
2024-03-14 |
2025-09-18 |
Thiogenesis Therapeutics, Inc. |
Pharmaceutically acceptable salts of cysteamine-pantetheine disulfide and uses thereof
|